Kathy E. Sietsema
UCLA Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kathy E. Sietsema.
American Journal of Kidney Diseases | 2001
Eric P. Brass; Sharon G. Adler; Kathy E. Sietsema; William R. Hiatt; Anthony M. Orlando; Antonino Amato; Chief Investigators
Exercise capacity in patients with end-stage renal disease (ESRD) remains impaired despite correction of anemia. Carnitine insufficiency may contribute to impaired exercise and functional capacities in patients with ESRD. Two randomized placebo-controlled trials were conducted to test whether intravenous L-carnitine improves exercise capacity (assessed by maximal rate of oxygen consumption [VO(2max)]) and quality of life (measured by the Kidney Disease Questionnaire [KDQ]) in patients with ESRD. In study A, patients were administered L-carnitine, 20 mg/kg (n = 28), or placebo (n = 28) intravenously at the conclusion of each thrice-weekly dialysis session for 24 weeks. In study B, a dose-ranging study, patients were administered intravenous L-carnitine, 10 mg/kg (n = 32), 20 mg/kg (n = 30), or 40 mg/kg (n = 32), or placebo (n = 33) as in study A. The prospective primary statistical analysis evaluated changes in VO(2max) in each study and specified that changes in the KDQ were assessed only in the combined populations. L-Carnitine supplementation increased plasma carnitine concentrations, but did not affect VO(2max) in either study. Because change in VO(2max) showed significant heterogeneity, a secondary analysis using a mixture of linear models approach on the combined study populations was performed. L-Carnitine therapy (combined all doses) was associated with a statistically significant smaller deterioration in VO(2max) (-0.88 +/- 0.26 versus -0.05 +/- 0.19 mL/kg/min, placebo versus L-carnitine, respectively; P = 0.009). L-Carnitine significantly improved the fatigue domain of the KDQ after 12 (P = 0.01) and 24 weeks (P = 0.03) of treatment compared with placebo using the primary analysis but did not significantly affect the total score (P = 0.10) or other domains of the instrument (P > 0.11). Carnitine was well tolerated, and no drug-related adverse effects were identified. Intravenous L-carnitine treatment increased plasma carnitine concentrations, improved patient-assessed fatigue, and may prevent the decline in peak exercise capacity in hemodialysis patients. VO(2max) in the primary analysis and other assessed end points were unaffected by carnitine therapy.
Biomarkers | 2010
Kathy E. Sietsema; Fanyu Meng; Nathan A. Yates; Ronald C. Hendrickson; Andy Liaw; Qinghua Song; Eric P. Brass; Roger G. Ulrich
Proteomics was utilized to identify novel potential plasma biomarkers of exercise-induced muscle injury. Muscle injury was induced in nine human volunteers by eccentric upper extremity exercise. Liquid chromatography–mass spectrometry identified 30 peptides derived from nine proteins which showed significant change in abundance post-exercise. Four of these proteins, haemoglobin α chain, haemoglobin β chain, α1-antichymotrypsin (ACT) and plasma C-1 protease inhibitor (C1 Inh), met the criterion for inclusion based on changes in at least two distinct peptides. ACT and C1 Inh peptides peaked earlier post-exercise than creatine kinase, and thus appear to provide new information on muscle response to injury.
European Journal of Applied Physiology | 1991
Issahar Ben-Dov; Kathy E. Sietsema; Karlman Wasserman
SummaryTo investigate the effect of hyperthyroidism on the pattern and time course of O2 uptake (
European Journal of Applied Physiology | 1994
Yong-Yu Zhang; Kathy E. Sietsema; Cynthia S. Sullivan; Karhnan Wasserman
The Cardiology | 1988
Karlman Wasserman; Kathy E. Sietsema
\dot V
American Journal of Nephrology | 2002
Eric P. Brass; Sharon G. Adler; Kathy E. Sietsema; Antonino Amato; Anne Esler; William R. Hiatt
Archive | 1991
Karlman Wasserman; A. Koike; Kathy E. Sietsema; Richard Casaburi
O2) following the transition from rest to exercise, six patients and six healthy subjects performed cycle exercise at an average work rate (WR) of 18 and 20 W respectively. Cardiorespiratory variables were measured breath-by-breath. The patients also performed a progressively increasing WR test (1-min increments) to the limit of tolerance. Two patients repeated the studies when euthyroid. Resting and exercise steady-state (SS)
Kidney International | 2004
Kathy E. Sietsema; Antonino Amato; Sharon G. Adler; Eric P. Brass
Chest | 1994
Kathy E. Sietsema; Issahar Ben-Dov; Yong-Yu Zhang; Cynthia S. Sullivan; Karlman Wasserman
\dot V
The American review of respiratory disease | 1992
Issahar Ben-Dov; Kathy E. Sietsema; Richard Casaburi; Karlman Wasserman